Human Immunodeficiency Virus (HIV) infected patients who meet the entry criteria for the maraviroc pivotal trials (Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients, MOTIVATE) will be identified from the EuroSIDA HIV cohort. The rates of specific clinical adverse events in this identified patient population will be compared with the rates of these events in the participants of the MOTIVATE trials.

All patients in EuroSIDA cohort that meet the entry criteria of MOTIVATE trials are included without any sampling.

Inclusion Criteria:

• Patient aged over 16 at baseline.
• Viral Load (VL) > 5000 copies/ml at baseline (and measured in 6 months prior to baseline).
• No changes in antiretroviral (ARV) regimens in the month period prior to baseline, or on no ARVs in the month prior to baseline.
• > 3 months exposure (sequential or cumulative) to at least 3 of the following;
• Any nucleoside or nucleotide reverse transcriptase inhibitor (NRTI)
• Non-nucleoside reverse transcriptase inhibitor (NNNRTI)
• Protease Inhibitor (PI )
• Enfuvirtide

Exclusion Criteria:

None

• Patient aged over 16 at baseline.
• Viral Load (VL) > 5000 copies/ml at baseline (and measured in 6 months prior to baseline).
• No changes in antiretroviral (ARV) regimens in the month period prior to baseline, or on no ARVs in the month prior to baseline.
• > 3 months exposure (sequential or cumulative) to at least 3 of the following;
• Any nucleoside or nucleotide reverse transcriptase inhibitor (NRTI)
• Non-nucleoside reverse transcriptase inhibitor (NNNRTI)
• Protease Inhibitor (PI )
• Enfuvirtide